Now I have enough calibration data. Let me compile the final review.

## Summary

This paper proposes HYPOGENEAGENT, an LLM-driven framework that uses the consistency of LLM-generated GO annotations as a criterion for selecting clustering resolution in single-cell/Perturb-seq analysis. The core idea is novel: an LLM generates ranked GO hypotheses for each cluster, and a Resolution Score combining intra-cluster agreement and inter-cluster distinctiveness (from sentence embeddings of those annotations) is maximized at the "best" resolution. Applied to a K562 CRISPRi dataset, the method selects resolutions r=0.4 (GEX level) and r=0.5 (perturbation level). Stage 1 provides a systematic benchmark of LLM backbones, prompt designs, and embedding methods on curated GOBP gene sets.

## Strengths

- **The conceptual framing is genuinely novel.** Prior work used LLMs for GO term generation only after clustering was fixed. The idea of feeding annotation consistency *back into* resolution selection — "none feeds functional feedback back into the clustering hyper parameters" (Section 2) — is a clear and well-identified gap that this paper targets. The Stage 1 parameter benchmark on 100 curated GOBP gene sets is competently designed, systematically comparing embedding methods (OpenAI, SapBERT, Nomic), prompt designs (general vs. hypothesis), LLM backbones (GPT-4o, GPT-o3, GPT-5, Gemini models), and temperature. The finding that thinking LLMs outperform non-thinking ones on the hypothesis task, and that GPT-o3's confidence scores correlate with semantic similarity to ground truth, are empirically useful results for anyone building gene-set annotation systems. The paper honestly acknowledges its limitations (scalability, generalizability, LLM dependence/cost, prompt sensitivity) in the conclusion.

## Weaknesses

### Major

- **The central claim — that the Resolution Score selects biologically meaningful clustering resolutions — is not validated against any independent ground truth.** The selected resolutions (r=0.4 at GEX, r=0.5 at perturbation level) are supported only by UMAP visualizations (Figures 3b, 4b) and by showing disagreement with traditional metrics (silhouette picks 0.5–0.6, modularity picks 0.7). The paper claims to "recover known perturbation effects" (abstract, conclusion) but provides no experiment checking whether clusters at the selected resolution better separate known perturbation targets (e.g., CRISPR guides targeting the same gene or pathway) than clusters at other resolutions. The K562 dataset from Replogle et al. 2022 has known perturbation labels that could serve this purpose, but they are not used.

- **The enrichment analysis in Section 4.4.3 undermines rather than supports the method.** Figure 6a (and its caption) explicitly state that the enrichment-based Resolution Score peaks at resolution 0.7 — not at 0.4 or 0.5. The paper dismisses this with an ad hoc justification: "consider the reasonability of cluster numbers we expected, so the selected resolution can be 0.5 or 0.4." This directly contradicts the claim of *objective* resolution selection and reveals that the authors fall back on the same subjective heuristics the method claims to replace.

- **Evaluation is limited to a single dataset** (K562 CRISPRi from Replogle et al. 2022). Despite this, the paper makes broad generalizability claims: "general-purpose tool for single-cell, perturb-seq and multi-omics analyses" and "paving the way for fully automated, context-aware interpretation pipelines" (abstract, conclusion). A single cell line (K562) cannot support these claims, especially given well-known batch effects and dataset-specific clustering behavior in single-cell analysis.

- **The comparison to traditional methods (silhouette, modularity, functional enrichment) merely documents disagreement** — each method picks a different resolution (0.5–0.6, 0.7, 0.7 vs. the proposed 0.4/0.5) — without providing any independent criterion to adjudicate which choice is better. Showing that methods disagree is not evidence that one is right. The paper presents this as a "comparison" but it is a staged demonstration, not a meaningful benchmark.

### Minor

- **No run-to-run variance analysis of the Resolution Score.** The LLM is stochastic (temperature effects are studied in Stage 1), yet the paper reports only a single run of the Resolution Score without assessing stability. Box plots show per-cluster distributions at each resolution, but there is no repeated-run analysis to establish whether the score curves are reproducible.

- **The agent architecture for evidence retrieval is under-specified.** Section 3.3 mentions retrieval from "GO, KEGG and PubMed" but gives no detail on the retrieval tool used, how results are filtered, or how retrieved snippets are incorporated into the prompt. Given that retrieval quality can dominate LLM performance on knowledge-grounded tasks, this is a significant omission for reproducibility and for understanding what drives the method's behavior.

- **The Resolution Score weight w=1/3 was chosen by "a small grid search" (Section 3.4) on a single dataset.** Sensitivity of the selected resolution to w is not shown in the main paper (deferred to Figure S5 in the appendix). If the optimal resolution shifts with different values of w, the choice becomes a critical hyperparameter requiring principled justification.

### Trivial

None.

## Nice-to-Haves

- Validating the chosen resolution against known perturbation targets (e.g., checking whether guides targeting the same gene/pathway cluster together better at r=0.4 than at other resolutions) would break the circularity and provide an external test of the method's central claim.
- Reporting LLM API costs and wall-clock time would substantiate the claim of "computationally efficient" and "orders of magnitude faster than manual curation."
- A small human evaluation (e.g., 5–10 clusters reviewed by a domain expert) would strengthen confidence that the LLM-generated annotations for real Perturb-seq clusters are accurate, beyond the Stage 1 validation on curated GOBP sets.
- Reporting the Resolution Score's sensitivity to weight w across the full range [0,1] in the main text (not just the appendix) would help assess robustness of the resolution choice.

## Removed Points

- *"Evaluation is circular by construction"* — This framing misrepresents the core design. The Resolution Score intentionally uses LLM annotation consistency as a proxy for biological coherence (that is the method, not a bug). The real gap (covered under the first Major weakness) is that Stage 1 only validates the LLM on curated GOBP sets, not on real Perturb-seq clusters. The circularity framing is misleading and was removed.
- *"S_k^cos confusion"* — The paper uses S_k^cos in Stage 1 (where reference descriptions exist) but not in the Resolution Score (Stage 2). The description is somewhat unclear but not incorrect; removed as minor.
- *"Closed models limit reproducibility"* — This is a common characteristic of applied LLM work; the paper acknowledges LLM dependence as a limitation. Not a unique weakness.
- *"No cost/runtime data" and "No human evaluation"* — Moved to Nice-to-Haves.
- *"Figure 6 resolution range inconsistency (0.1–0.9 vs 0.1–1.0)"* — Minor formatting observation; parser-level artifact risk.
- *"'The best solution is characterized by...' is tautological"* — This describes the empirical finding, not a claimed discovery. The paper reports that both ICS and ICD components peak at r=0.4; this is a factual observation about the data, not a tautology.

## Novel Insights

None beyond the paper's own contributions.

## Calibration Anchors

| Anchor Path | Avg Score | Round | Itemized | Comparison |
|---|---|---|---|---|
| `nUpM7egYFd.md` (scMPT) | 3.40 | R1 (1.5–3.5) | Yes | Similar in combining LLMs with single-cell analysis, but scMPT has broader literature awareness while HypoGeneAgent has a more novel core idea. Both suffer from validation gaps. |
| `HAwZGLcye3.md` (BioDiscoveryAgent) | 6.40 | R1 (5.5–7.5) | Yes | Both use LLM agents for biological discovery, but BioDiscoveryAgent has thorough multi-dataset validation, extensive baselines, and clear empirical results. HypoGeneAgent is substantially weaker on all these dimensions. |
| `iOltCu4TPS.md` (Single-cell retrieval benchmark) | 5.00 | R1 (3.5–5.5) | Yes | Both benchmark methods, but this anchor is a pure evaluation paper. Not directly comparable in contribution type. |
| `J1xtkJmFY3.md` (ZerOmics) | 4.67 | R1 (3.5–5.5) | Yes | Both apply LLMs to single-cell tasks. ZerOmics has stronger architecture novelty but its "zero-shot" claim was found overstated. HypoGeneAgent has a more original framing but weaker validation. |
| `PQrkWvQSL0.md` (DrugAgent) | 2.50 | R2 (1.0–4.0) | Yes | Multi-agent LLM for biology. Much weaker novelty and evaluation than HypoGeneAgent; a clear strong reject. HypoGeneAgent is significantly stronger. |
| `K1bv86Uvbp.md` (LLM for KG construction) | 3.00 | R2 (1.0–4.0) | Yes | Similarly limited validation and lack of comparison to prior art, but also suffers from poor writing and formatting. HypoGeneAgent is better on clarity and Stage 1 rigor. |
| `jLd7OyAD4Y.md` (LLM4GRN) | 4.33 | R2 (3.0–5.0) | Yes | Both use LLMs for biological discovery without ground truth. LLM4GRN addresses the gap through synthetic data generation; HypoGeneAgent's enrichment analysis actually contradicts its own method. HypoGeneAgent has more conceptual novelty. |
| `VdX9tL3VXH.md` (sCellTransformer) | 4.50 | R2 (3.0–5.0) | No | Single-cell foundation model; not directly comparable in method type but sits in similar score range. |

**Round 1 bracket**: The paper's novelty (weight +1.40) and Stage 1 rigor (+3.34) outweighed by four weaknesses each at -4.93 to -6.41. Comparing against BioDiscoveryAgent (6.40) with +4.7–+5.3 strength weights and scMPT (3.40) with similar validation gaps, the bracket was initially 3.0–5.0.

**Final calibration**: The paper is stronger than DrugAgent (2.50) and KG-construction LLM (3.00) — it has clearer writing, better motivation, and a genuinely novel core idea. It is weaker than BioDiscoveryAgent (6.40) and somewhat weaker than LLM4GRN (4.33) in terms of validation depth. The enrichment analysis contradiction (Figure 6a peaking at 0.7, not 0.4/0.5) is a specific, verifiable problem that neither scMPT nor ZerOmics has, and it directly undermines the claim of "objective" resolution selection. Weighted-item comparison shows the four major weaknesses (cumulative -21.7) significantly outweigh strengths (+5.2), placing this paper below LLM4GRN (4.33) which at least attempts an indirect validation strategy.

## Suggestions

1. Validate the chosen resolution against known perturbation classes in the K562 data (e.g., check whether guides targeting the same gene cluster together better at the selected resolution than at others). This single experiment would directly test the central claim.
2. Test on at least one additional dataset (e.g., a different cell line or tissue) before making generalizability claims.
3. Explain or correct the enrichment analysis contradiction (Figure 6a peaking at 0.7 vs. the claimed 0.4/0.5). If the method disagrees with functional enrichment, that needs a principled explanation, not an appeal to "reasonability of cluster numbers."
4. Report run-to-run variance of the Resolution Score curve, and show how the optimal resolution changes as weight w varies across [0,1].
5. Tone down the language: "recovers known perturbation effects" and "general-purpose tool" are not supported by the evidence presented.
6. Provide more detail on the evidence retrieval pipeline (Section 3.3): which tool, how snippets are filtered and incorporated.

## Score and Decision

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>